SULM – Schweizerische Union für Labormedizin | Union Suisse de Médecine de Laboratoire | Swiss Union of Laboratory Medicine

Sie sind hier | Vous êtes ici:

Serenay Elgun1 , Hanefi Ozbek2 , Ilker Durak1

1Department of Biochemistry, Ankara University School of Medicine, Ankara, Turkey., 2Department of Pharmacology, 100. Yil University School of Medicine, Van, Turkey

Objective: Carboplatin and its analogs are effective against solid tumors. Oxygen free radicals are also thought to play part in the damage of neoplastic cell DNA (1). Carboplatin has lower nonhematological adverse effects compared to its analogs, one of which is hepatotoxicity. In this study, we aimed to investigate whether oxidative stress has a role in both antitumoral cytotoxicity of carboplatin and in its adverse effect in liver.
Methods: Twelve rats were used in the study. Carboplatin was given intraperitoneally (25 mg/kg/day) for 5 days. Controls were treated with intraperitoneal physiological saline. After the animals were sacrificed, their livers were homogenised and used for glutathione peroxidase (GSH-Px) activity, malondialdehyde (MDA) level and antioxidant potential determination(3, 4, 5).
Results: Hepatic tissue GSH-Px activity and antioxidant potential were found to be decreased while MDA level increased in carboplatin treated group compared to the control group.
Summary and Conclusion: Carboplatin decreases the antioxidant potential of hepatic tissue probably through inhibition of GSH-Px activity. As a consequence, lipid peroxidation increases. This might be a mechanism by which carboplatin decreases the survival rate of cancer cells since lipid peroxidation may lead to the damage of neoplastic cells. On the other hand, carboplatin induced free radical generation and antioxidant potential decrease cause oxidative injury in hepatic tissue which may be the reason of hepatotoxicity caused by this drug.
1.Drewa T, Wozniak A, Drewa G, Olszewska D, Wozniak B, Wysocki M et al. Med Sci Monit 2001;7:680-6.
2.Paglia DE, Valentine WN. J Lab Clin Med 1967;70:158-69.
3.Van Ye TM, Roza AM, Pieper GMJ, Henderson JR, Johnson CP, Adams MB. J Surg Res 1993;55:553-8.
4.Durak I, Karabacak HI, Büyükkoçak S, Çimen MYB, Kaçmaz M, Ömeroglu E et al. Nephron 1998;78:207-11.


07. & 08.03.2019: Swiss eHealth Forum - Digitales Gesundheitswesen – Hope and > mehr


pipette 06/2018: Die Analyse der Darmflora | Analyse du microbiote

Aktuelle Ausgabe als E-Paper lesen


17.12.2018: Cheflaboranten/in 80%, (HFR) Tafers